Vera Therapeutics receives Investment Bank Analyst Rating Update
By Senad Karaahmetovic Shares of Vera Therapeutics (NASDAQ:VERA) are trading more than 50% lower in pre-market Wednesday after the company presented the results from its Phase...
After-Hours Movers: Vera Therapeutics Inc (NASDAQ:VERA) 62% LOWER; announced the Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN)...
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus. The Company is also planning to initiate a Phase III clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of Systemic Lupus Erythematosus (SLE).
|Average||29.14 (+233.44% Upside)|
|No. of Analysts||7|